JOURNAL ARTICLES AND OTHER PROFESSIONAL PUBLICATIONS BY SUBJECT

ADDICTION TREATMENT

DuPont, R. L., Garcia-Rosales, K., Shea, C. L., DuPont, H., Campbell, M. D., Kolodner, G., & Wish, E. (2017). Are prescription opioids creating a new type of heroin user? The Journal of Global Drug Policy and Practice, 11(1). 

DuPont, R. L. (2016). Getting serious about substance abuse treatment requires adopting the five-year recovery standard. Journal of Global Drug Policy and Practice, 10(3). 

DuPont, R. L. (2016, September 12). Benzodiazepines and addiction: new thinking about old drugs. Kolmac Outpatient Recovery Centers Blog. 

DuPont, R. L. (2016, August 5). Seizing the moment to improve addiction treatment. ASAM Magazine. [Related Commentary by A. Thomas McLellan, PhD]

Campbell, M. D., Kolodner, G., Spencer, R. A. & DuPont, R. L. (2016). Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program. Journal of Addictive Diseases. 

DuPont, R. L., Seppala, M. D. & White, W. L. (2015). The three missing elements in the treatment of substance use disorders: lessons from the physician health programs. Journal of Addictive Diseases, 35(1), 3-7.

DuPont, R. L., Compton, W. M. & McLellan, A. T. (2015). Five-year recovery: A new standard for assessing effectiveness of substance use disorder treatment. Journal of Substance Abuse Treatment, 58, 1-5.

White, W. L., Campbell, M. D., Spencer, R. D., Hoffman, H. A., Crissman, B., & DuPont, R. L. (2014). Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. Journal of Psychoactive Drugs, 46(2), 114-122.

White, W. L., Campbell, M. D., Spencer, R. A., Hoffman, H. A., Crissman, B., & DuPont, R. L. (2014). Participation in Narcotics Anonymous and Alcoholics Anonymous and abstinence outcomes of 322 methadone maintenance patients. Journal of Groups in Addiction & Recovery, 9(1), 14-30.

PHYSICIAN HEALTH PROGRAMS

DuPont, R. L., & Gold, M. S. (2020, March 18). Should physicians with OUDs return to practice after treatment? New review points to importance of sustained recovery [Commentary]. Clinical Psychiatry News.

DuPont, R. L., & Merlo, L. J. (2018). Physician health programs: a model for treating substance use disorders. The Judges’ Journal, 57(1), 32-35.

Carr, G. D., Hall, B., Finlayson, A. J. R., & DuPont, R. L. (2017). Physician health programs: the US model. In K. J. Brower & M. B. Riba (Eds.), Physician Mental Health and Well-Being: Integrating Psychiatry and Primary Care (pp. 265-294). Cham, Switzerland: Springer International Publishing.

Merlo, L. J., & DuPont, R. L. (2016). Essential components of physician health program participation: perspectives of participants five years post-graduation. Physician Health News, 1, 14-15.

Merlo, L. J., Campbell, M. D., Skipper, G. E., Shea, C. L., & DuPont, R. L. (2016). Outcomes for physicians with opioid dependence treated without agonist pharmacotherapy in physician health programs. Journal of Substance Abuse Treatment, 64, 47-54.

Finlayson, A. J. R., Iannelli, R. J., Brown, K. P., Neufeld, R. E., DuPont, R. L., & Campbell, M. D. (2016). Physician suicide and physician health programs. General Hospital Psychiatry.

DuPont, R. L. (2016). An outsider looks at PHP care management. Physician Health News, 21, 7-8.

Braquehais, M. D., Tresidder, A. & DuPont, R. L. (2015). Service provision to physicians with mental health and addiction problems. Current Opinion in Psychiatry, 28(4), 324-329.

Rose, J. S., Campbell, M. D., & Skipper, G. E. (2014). Prognosis for emergency physician with substance abuse recovery: 5-year outcome study. Western Journal of Emergency Medicine, 15(1).

Yellowlees, P. M., Campbell, M. D., Rose, J. S., Parish, M. B., Ferrer, D., Scher, L. M., Skipper, G. E., & DuPont, R. L. (2014). Psychiatrists with substance use disorders: positive treatment outcomes from physician health programs. Psychiatric Services, doi: 10.1176/appi.ps.201300472

DuPont, R. L., & Skipper, G. E. (2012). Six lessons from physician health programs to promote long-term recovery. Journal of Psychoactive Drugs, 44(1), 72-78.

Buhl, A., Oreskovich, M. R., Meredith, C. W., Campbell, M. D., & DuPont, R. L. (2011). Prognosis for the recovery of surgeons from chemical dependency. Archives of Surgery, 146(11), 1286-1291.

Skipper, G. E., Campbell, M. D. & DuPont, R. L. (2009). Anesthesiologists with substance use disorders: A 5-year outcome study from 16 state Physician Health Programs. Anesthesia & Analgesia, 109(3), 891-896. 

DuPont, R. L., McLellan, A. T., Carr, G., Gendel, M & Skipper, G. E. (2009). How are addicted physicians treated? A national survey of physician health programs. Journal of Substance Abuse Treatment, 37, 1-7.

DuPont R. L., McLellan A. T., White W. L., Merlo L., and Gold M. S.  (2009). Setting the standard for recovery: Physicians Health Programs evaluation review. Journal for Substance Abuse Treatment, 36(2), 159-171.

McLellan, A. T., Skipper, G. E., Campbell, M. G. & DuPont, R. L. (2008). Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. British Medical Journal, 337:a2038.

DRUGGED DRIVING

Larkin, P. J., DuPont, R. L., & Madras, B. K. (2018, May 16). The Need to Treat Driving Under the Influence of Drugs as Seriously as Driving Under the Influence of Alcohol. Backgrounder, 3316. Washington, DC: The Heritage Foundation.

Talpins, S. K., DuPont, R. L., Walls, C. H., Sabet, K., & Wallace, D. (2015). The Miami-Dade protocol: making drugged driving enforcement a reality. Journal of Alcohol and Drug Dependence, 3(4), 212-213.

DuPont, R. L., & Shea, C. L. (2014, August). The public safety threat of drugged driving. Need to Know. Alexandria, VA: National Association of Drug Court Professionals.

Talpins, S. K., DuPont, R. L, Voas, R. B., Holmes, E., Sabet, K. A., & Shea, C. L. (2014). License to revocation as a tool for combating drugged driving. Impaired Driving Update, 18(2). 

DuPont, R. L, Talpins, S. K., & Shea, C. L. (2013). Commentary on Romano & Pollini (2013): Stopping drug-impaired driving and alcohol-impaired driving—synergy, not competition. Addiction, 108(8), 1439-1440.

Voas, R. B., DuPont, R. L., Shea, C. L., & Talpins, S. K. (2013). Prescription drugs, drugged driving and per se laws. Injury Prevention, 19(3), 218-221.

Reisfield, G. M., Goldberger, B. A., Gold, M. S., & DuPont, R. L. (2012). The mirage of impairing drug concentration thresholds: A rationale for zero tolerance per se driving under the influence of drugs laws. Journal of Analytical Toxicology, 36(5), 353-356. 

DuPont, R. L., Voas, R. B., Walsh, J. M., Shea, C., Talpins, S. K., & Neil, M. M. (2012). The need for drugged driving per se laws: A commentary. Traffic Injury Prevention, 13(1), 31-42.

NATIONAL DRUG TRENDS AND POLICY

Compton, W. M., Valentino, R. J., & DuPont, R. L. (2021). Polysubstance use in the U.S. opioid crisis. Molecular Psychiatry, 26, 41-50.

Coleman, J. J., & DuPont, R. L. (2019, September 4). Fentanyl as sentinel: the deadly threat of illegal synthetic and counterfeit drugs. [Backgrounder]. Washington, DC: The Heritage Foundation.

DuPont, R. L. (2019, April 16). Drug crises over the horizon. [Backgrounder]. Washington, DC: The Heritage Foundation.

DuPont, R. L. (2018). A new narrative to understand the opioid epidemic. The Journal of Global Drug Policy and Practice, 12(1).

Han, B., Compton, W. M., Blanco, C., & DuPont, R. L. (2017). National trends in substance use and use disorders among youth. Journal of the American Academy of Child & Adolescent Psychiatry, 56(9), 747-754.

Bennett, W., & DuPont, R. L. (2017, June 29). Getting the opioid epidemic right. The Daily Signal.

DuPont, R. L. (2016, April 26). Marijuana has proven to be a gateway drug [Room for Debate]. The New York Times. 

DuPont, R. L. (2015). The global drug problem: an introduction. In Drug Policy Futures, Future of Drug Policy: Real Solutions Grounded in Global Evidence (pp. 7-9). Stockholm, Sweden: Drug Policy Futures.

Wish, E. D., Artigiani, E., Billing, A., Hauser, W., Hemberg, J., Shiplet, M., DuPont, R. L. (2012). The emerging buprenorphine epidemic in the United States. Journal of Addictive Diseases, 31(1), 3-7.

DuPont, R. L., Madras, B. K. & Johansson, P. (2011). Drug policy: a biological science perspective. In J. H. Lowinson & P. Ruiz (Eds.) Substance Abuse: A Comprehensive Textbook (5th ed., pp. 998-1010). Philadelphia, PA: Lippincott Williams & Wilkins. 

DRUG AND ALCOHOL TESTING

DuPont, R. L. (2017, July/August). New trends in workforce drug use. Risk Management, 14-15.

DuPont, R. L. (2015, Fall). Drug testing and legal marijuana: What should contractors do? The Construction User, 14-15, 23.

Skipper, G. E., Thon, N., DuPont, R. L., Campbell, M. D., Weinmann, W., & Wurst, F. M. (2014). Cellular photo digital for monitoring alcohol use: a pilot study. European Addiction Research, 20(3), 137-142.

Skipper, G. E., Thon, N., DuPont, R. L., Baxter, L., & Wurst, F. M. (2013). Phosphatidylethanol: the potential role in further evaluating low positive urinary ethyl glucuronide and ethyl sulfate results. Alcoholism, Clinical and Experimental Research, 37(9), 1582-158. 

DuPont, R. L., Martin, D. M., & Skipper, G. E. (2012). A new challenge for drug-free workplace programs. Occupational Health and Safety, 81(2).

Reisfield, G. M., Shults, T., Demery, J., & DuPont, R. L. (2013). A protocol to evaluate drug-related workplace impairment. Journal of Pain and Palliative Care Pharmacotherapy, 27(1), 43-48.

Morrison, R. A., & DuPont, R. L. (2013). The new paradigm and the DOT/SAP process. Journal of Employee Assistance, 43(1), 26-28.

PREVENTION

DuPont, R. L., & DuPont, C. (2019). A renewed focus on youth prevention use prevention is needed among health care professionals and parents. JAMA Network Open, 2(11), e1916058.

King, S. M., McGee, J., Winters, K. C., & DuPont, R. L. (2019). Correlates of substance use abstinence and non-abstinence among high school seniors: results from the 2014 Monitoring the Future survey. Journal of Adolescent Substance Abuse, 28(2), 105-112.

Levy, S., Campbell, M. C., Shea, C. L., & DuPont, R. L. (2018). Trends in abstaining from substance use in adolescents: 1975-2014. Pediatrics, doi: 10.1542/peds.2017-3498.

DuPont, R. L., Han, B., Shea, C. L., & Madras, B. K. (2018). Drug use among youth: national survey data support a common liability of all drug use. Preventive Medicine, 113, 68-73.

Visit www.OneChoicePrevention.org or www.PreventTeenDrugUse.org

DuPont, R. L. (2017). The opioid epidemic is an historic opportunity to improve both prevention and treatment. Brain Research Bulletin. 

Levy, S., DuPont, R. L., Fishman, M. J., & Hadland, S. (2017, September 28). Teen substance use declining, but addiction persists. Thrive Global.

DuPont, R. L. (2016, May 23). Drug abuse prevention should be about health: no use of alcohol, nicotine, marijuana and other drugs for reasons of health. CADCA Blog. 

DuPont, R. L., Merlo, L. J., Arria, A. M., & Shea, C. L. (2013). Random student drug testing as a school-based drug prevention strategy. Addiction, 108(5), 839-845.

DuPont,  R. L., Campbell, M. D., Campbell, T. G., Shea, C. L., & DuPont, H. S. (2013). Self-reported drug and alcohol use and attitudes toward drug testing in high school with random student drug testing. Journal of Child & Adolescent Substance Abuse, 22(2), 104-119.

DuPont, R.L., & Bucher, R.H. (2012). Guide to responsible family drug and alcohol testing. Rockville, MD: Institute for Behavior and Health, Inc.

MEDICAL MARIJUANA

DuPont, R. L. (2016, August 25). Should patients with cancer be offered cannabis as a pain management strategy? No. [Point/Counter]. HemOnc Today.

Reisfield, G. M., & DuPont, R. L. (2013). Recommend against the medicinal use of marijuana [Clinical Decisions]. New England Journal of Medicine, 368(9), 886-868. 

Kleber, H. D., & DuPont, R. L. (2012). Physicians and medical marijuana. American Journal of Psychiatry, 169(6), 564-568.